You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱景生物(688068.SH)2021年度預盈20億-23.5億元 同比增加1684.65%-1996.97%
格隆匯 01-06 17:16

格隆匯1月6日丨熱景生物(688068.SH)公佈,預計2021年年度實現歸屬於母公司所有者的淨利潤20億元至23.5億元,與上年同期(法定披露數據)相比,將增加18.88億元至22.38億元,同比增加1684.65%至1996.97%;

歸屬於母公司所有者的扣除非經常性損益的淨利潤19.87億元至23.37億元,與上年同期(法定披露數據)相比,將增加18.76億元至22.26億元,同比增加1696.17%至2012.59%。

2020年,受新冠疫情以及國內新冠抗體檢測試劑獲證較晚影響,公司經營業績相對較小,導致與2021年對比基數較小。

2021年,上半年公司的新型冠狀病毒抗原檢測試劑盒較早獲得德國聯邦藥品和醫療器械研究所(BfArM)用於居家自由檢測的認證,可以在德國的商超、藥店、互聯網商店等銷售,導致上半年公司的外貿訂單爆發式增長;下半年,研發的公司新型冠狀病毒抗原測定試劑盒先後獲得了歐盟CE以及英國MHRA、法國ANSM等主要經濟體的自測註冊/備案,並在第四季度受新冠病毒德爾塔和奧密克戎變異影響,歐洲、東南亞等國家和地區新冠疫情居高不下,導致對新冠抗原檢測試劑需求大幅增加時,實現了海外新冠檢測試劑收入的大幅增長;導致2021年公司業績相比去年同期實現較大規模增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account